Application of faropenem in preparation of medicine for initial treatment of pathogen-positive pulmonary tuberculosis

A faropenem and pulmonary tuberculosis technology, applied in the field of medicine, can solve the problems of high toxicity and side effects, long course of treatment, etc., and achieve the effect of high cure rate, fast onset of effect, and small side effects

Inactive Publication Date: 2020-05-22
LUNAN PHARMA GROUP CORPORATION
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0007] In order to overcome the defects of long tuberculosis treatment course and high toxicity and side effects in the prior art, the present invention provides the use of faropenem in the preparation of a drug for the treatment of newly diagnosed etiologically positive pulmonary tuberculosis

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of faropenem in preparation of medicine for initial treatment of pathogen-positive pulmonary tuberculosis
  • Application of faropenem in preparation of medicine for initial treatment of pathogen-positive pulmonary tuberculosis
  • Application of faropenem in preparation of medicine for initial treatment of pathogen-positive pulmonary tuberculosis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0033] Example 1 Determination of MIC of each drug on Mycobacterium tuberculosis

[0034] The human tuberculosis standard strain H37Rv (purchased from Shandong Institute of Tuberculosis Prevention and Treatment, batch number: 170308) was inoculated into Roche slant medium and cultured at 37°C for 4 weeks. Centrifuge the appropriate amount of culture and mix it with physiological saline. After 25 minutes of precipitation, take the upper bacterial solution and place it on the Roche slant medium containing different concentrations of drugs. The inoculum concentration is 10 6 CFU / point, cultivate at 37°C until colonies are formed in the growth control tube, observe and record the results.

[0035] The preparation method of the drug-containing Roche slant medium is the same as that of the ordinary Roche slant medium, and the medicine is added to the medium before the medium is added to the test tube.

[0036] The drugs used in the experimental group were: Faropenem, Pyrazinamide and Rifa ...

Embodiment 2

[0042] Example 2 Clinical trial to investigate the therapeutic effect of faropenem on newly diagnosed pathogen-positive pulmonary tuberculosis

[0043] 1. Case inclusion

[0044] (1) Case inclusion criteria

[0045] 1) Patients diagnosed with tuberculosis for the first time with positive pathogen identification, including sputum smear-positive, sputum culture-positive, GeneXpert-positive, among them, sputum smear-positive, sputum culture-positive patients are identified as Mycobacterium tuberculosis.

[0046] 2) Age 18 to 80 years old.

[0047] 3) The susceptibility of sputum bacteria confirmed that there is no resistance to isoniazid and rifampicin.

[0048] 4) The liver and kidney functions are normal.

[0049] 5) Imaging shows lung tuberculosis lesions.

[0050] 6) No HIV infection.

[0051] (2) Case exclusion criteria:

[0052] 1) Pulmonary tuberculosis combined with extrapulmonary tuberculosis.

[0053] 2) A history of allergies to any drugs in the protocol.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention belongs to the technical field of medicines, and relates to a new application of faropenem, in particular to the new application of the faropenem in preparation of a medicine for initialtreatment of pathogen-positive pulmonary tuberculosis. Compared with an existing standard scheme, when being used for initial treatment of the pathogen-positive pulmonary tuberculosis, a pharmaceutical composition containing the faropenem is remarkable in effect, rapid in effect taking, small in side effect and high in safety, and effectively overcomes the defects that the tuberculosis treatmentis long in treatment course and high in toxic and side effects.

Description

Technical field [0001] The invention belongs to the technical field of medicine, and relates to the new use of faropenem, in particular to the new use of faropenem in the preparation of a medicine for treating newly-treated pathogen-positive tuberculosis. Background technique [0002] Tuberculosis is a contagious disease, among which tuberculosis patients who can detect Mycobacterium tuberculosis in sputum are infectious and can be transmitted through the air; each patient with infectious tuberculosis can infect 10-15 people per person per second; Some people around the world are infected with Mycobacterium tuberculosis. According to the World Health Organization, nearly one-third of people in the world have been infected with Mycobacterium tuberculosis. There are about 20 million active tuberculosis patients in the world, about 8-10 million new tuberculosis patients each year, and about 3 million people die of tuberculosis each year. [0003] The inadequacy of the health service...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/431A61P31/06A61K31/4965A61K31/496A61K31/4409
CPCA61K31/431A61K31/4409A61K31/496A61K31/4965A61P31/06A61K2300/00
Inventor 张贵民孙成宏王升兰
Owner LUNAN PHARMA GROUP CORPORATION
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap